Radiation physiology – evidence for a higher biological effect of 24 Gy in four fractions as compared to three

G. Steineck,Cecilia Bull,M. Kalm,F. Sjöberg,Eleftheria Alevronta,D. Malipatlolla,K. Bergmark,B. Jeppsson,U. Wilderäng,T. Björk-Eriksson

DOI: https://doi.org/10.1080/0284186X.2017.1309062

IF: 4.311

2017-04-05

Acta Oncologica

Abstract:has the most profound effect on drug exposure, cobicistat was administered concomitantly with the axitinib to maximize the effect of CYP3A inhibition [7]. In a study by Pithavala et al., the effect of ketoconazole, a potent CYP3A4 inhibitor, on axitinib exposure was investigated. A twofold increase on axitinib exposure was seen when axitinib was concomitantly ingested with ketoconazole. Cobicistat is a more potent 3A4 inhibitor than ketoconazole therefore a more than twofold increase in axitinib exposure was expected [8]. Interestingly, during co-administration with cobicistat, axitinib trough levels did not significantly increase even though the C2 level did increase. The clinical response in the absence of sufficient trough levels can possibly be explained by the over-expression of CYP3A enzymes in tumor cells in patients with renal cell cancer [9]. This could indicate that axitinib is not only metabolized systemically in the liver, but also intracellularly in tumor cells. Inhibiting CYP3A metabolism by adding cobicistat to axitinib therapy could potentially increase the intracellular axitinib concentration by inhibiting the intratumorcel CYP3A enzymes, leading to an increased intracellular exposure of axitinib resulting in a more effective treatment. Here, we described an mRCC patient treated with cobicistat boosted axitinib treatment. This resulted in increased axitinib exposure and improved the quality of life by reduction of ascites. The patient responded to cobicistat boosted axitinib therapy for 15 months compared with 8.3 months, which is seen on average [10]. Although our observations have to be explored further, we believe that boosting axitinib exposure with cobicistat may be a promising and cost-effective way to increase axitinib response in patients with treatment failure hypothetically due to sub-optimal exposure. References